Market Overview

Morgan Stanley Adjusts Their View Of Biogen After Spinoff

Morgan Stanley Adjusts Their View Of Biogen After Spinoff
Related BIIB
Reasons To Be Optimistic On Biogen's Alzheimer's Treatment Prospects
The Market In 5 Minutes: Black Friday Closes Shortened Trading Week
John Paulson's Largest 'rd Quarter Trades (GuruFocus)

Biogen Inc (NASDAQ: BIIB) published a Form 10 for its hemophilia spin-off, Bioverativ. Morgan Stanley’s Matthew Harrison maintained an Overweight rating on the company, while reducing the price target from $385 to $368. The analyst revised the Biogen model to remove Hemophilia estimates from 2017 onwards.

Updates To The Model

Biogen’s spin-off of its hemophilia assets is expected to be completed in early 2017. Analyst Harrison mentioned the following updates to the Biogen model:

  • All hemophilia costs and revenues after 2016 have been removed. Consequently, the revenue estimates for 2017 and 2018 have been reduced by 7.3 percent and 7.4 percent, respectively.
  • The SG&A and R&D estimates for both 2017 and 2018 have both been reduced by 6.3 percent. These expenses have been reduced for 2017 onward by two-third of the total Bioverativ spending, which is $225 million for SG&A and $200 million for R&D, assuming some dis-synergies of the split.
  • The tax rate in 2017 and beyond has been reduced by 1 percent to reflect that the hemophilia assets carry a full statutory US tax rate, since the IP is US domiciled.

Related Link: Jefferies Upgrades Avexis To Buy Following Positive AVXS-101 Data, Doc Feedback

“We also updated our hemophilia revenue ramps to better reflect competitor timelines to the market and the slope of the European launches which just began in early 2016,” Harrison wrote.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for BIIB

Nov 2016MizuhoInitiates Coverage OnNeutral
Nov 2016Leerink SwannUpgradesMarket PerformOutperform
Nov 2016PiperJaffrayUpgradesNeutralOverweight

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Price Target Reiteration Analyst Ratings Trading Ideas Best of Benzinga


Related Articles (BIIB)

View Comments and Join the Discussion!